Issue: 2017 > June > case report

Transient thyrotoxicosis during nivolumab treatment



CASE REPORT
M.J. van Kooten1, G. van den Berg, A.W.J.M. Glaudemans, T.J.N. Hiltermann, H.J.M. Groen, A. Rutgers, T.P. Links
AbstractFull textPDF

Abstract

Two patients presented with transient thyrotoxicosis within 2-4 weeks after starting treatment with nivolumab. This thyrotoxicosis turned into hypothyroidism within 6-8 weeks. Temporary treatment with a beta blocker may be sufficient.